NCT07734753Completed
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
Alirocumab and Cardiovascular Outcomes in Patients Without a Previous Myocardial Infarction or Stroke
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 4006 (actual)
- First submitted
- 24 Jul 2026
- Start date
- 15 Jul 2025
- Primary completion date
- 15 May 2026
- Lead sponsor
- Sanofi
- Diseases
- Stroke
- NCT number
- NCT07734753
What you commit to
- Study type: Observational
- Participants enrolled: 4006
- From 15 Jul 2025 to the primary completion date, 15 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Participants with a history of prior ischemic events.
Other
- The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Who the study is looking for
- Adults aged ≥18 years with documented ASCVD between January 1, 2016, and September 30, 2024.
- No history of myocardial infarction, ischemic stroke, or hospitalization for unstable angina on or before the index date.
- Minimum of 12 months of continuous healthcare data availability prior to the index date
- No exposure to any PCSK9 inhibitor in the 2 years preceding the index date.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sanofi Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.